Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

Summary

This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years;
* American Society of Anesthesiologists (ASA) physical status I-III;
* Body mass index (BMI) 18-30 kg/m²;
* Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;
* Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3;
* Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities;
* No infection around the acupuncture sites;
* Voluntary written informed consent provided by the subject.

Exclusion Criteria:

* Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function;
* Subjects with cognitive dysfunction or psychological disorders;
* History of previous esophageal or gastric surgery;
* Hypersensitivity to acupuncture or any study medications;
* Severe infection or history of surgery around the acupuncture sites;
* Pregnant or lactating women;
* Long-term opioid use;
* Conversion to open surgery;
* Acupuncture treatment received within 1 month prior to enrollment.

Conditions3

Interventions1

Browse More Trials